Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Respiratory syncytial virus, or RSV, is a virus that causes infections of the lungs and breathing passages. It is highly ...

Oct. 30—(StatePoint) Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to respiratory syncytial virus (RSV). RSV is a highly contagious ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

“Respiratory syncytial virus does present differently in ... affects your larger airways and usually happens to older children and adults.) “The best protection we have—in addition to ...

Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD.

Previously, the adjuvanted RSV prefusion F protein-based vaccine had been approved only for adults ages 60 and older. Then in ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.